Genomic profiling of the residual disease of advanced high‐grade serous ovarian cancer after neoadjuvant chemotherapy-Reference-Cited by-同舟云学术

Genomic profiling of the residual disease of advanced high‐grade serous ovarian cancer after neoadjuvant chemotherapy

Published:2019-11-23 Issue:7 Volume:146 Page:1851-1861
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Lee Yong J.¹,Kim Dachan²,Shim Jung E.³,Bae Su‐Jin⁴,Jung Yu‐Jin⁴,Kim Sora⁵,Lee Hanna⁴,Kim So H.¹,Jo Su B.¹,Lee Jung‐Yun¹^ORCID,Kim Hyun‐Soo⁶,Paik Soonmyung⁴

Affiliation:

1. Department of Obstetrics and Gynecology, Institute of Women's Life Medical ScienceYonsei University College of Medicine Seoul Republic of Korea

2. Department of MedicineYonsei University College of Medicine Seoul Republic of Korea

3. Yonsei Biomedical Research InstituteYonsei University College of Medicine Seoul Republic of Korea

4. Severance Biomedical Science InstituteYonsei University College of Medicine Seoul Republic of Korea

5. Department of Biomedical Systems Informatics, Bran Korea 21 PLUS Project for Medical SciencesYonsei University College of Medicine Seoul Republic of Korea

6. Department of Pathology, Severance HospitalYonsei University College of Medicine Seoul Republic of Korea

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32729

Reference34 articles.

1. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

2. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer